Biotech Drug Report Generated Jul 9, 2026

DA-1726

MTVA·MetaVia Inc.

MIXED

Drug Impact Rating7/10

Trial Phase: Phase 1
Time to Market: At least 5-7 years, assuming successful Phase 2 and Phase 3 trials
Why 7/10: The next hard, dated catalyst is topline Phase 1 Part 3 data expected in Q4 2026 (~3-5 months away). This is the company's lead asset driving most of the thesis at a ~$8M market cap, but it's a Phase 1 (not pivotal) readout, and the company has a secondary pipeline program (vanoglipel), capping the score at 7.

Actionable Insight MIXED

DA-1726 is MetaVia's lead asset in a hyper-competitive obesity market. The Q4 2026 Phase 1 Part 3 topline readout is the key catalyst. Strong data could drive a massive percentage move given the ~$8M micro-cap valuation, but dilution risk is acute (ATM offering expanded to $4M with $2.1M already sold).

Price Chart

Loading chart...

Executive Summary

DA-1726 is MetaVia Inc.'s lead drug candidate — a GLP-1/glucagon dual agonist (a type of obesity treatment) currently in Phase 1 trials. Early data showed 9.1% mean weight loss at 48mg over 8 weeks, which is competitive with established drugs but was from a small, early-stage cohort. The company just completed dose titration on Part 3 (higher doses up to 64mg), with topline data due Q4 2026. MetaVia has a tiny ~$8M market cap, heavy dilution via an ATM offering, and faces overwhelming competition from Novo Nordisk, Eli Lilly, and Boehringer Ingelheim/Zealand Pharma whose survodutide just showed 16.6% weight loss in Phase 3. The stock is a binary bet on the Phase 1 readout — success could yield enormous percentage returns given the micro-cap, but the odds are long.

How It Works

DA-1726 is a synthetic copy of a natural gut hormone called oxyntomodulin. It activates two receptors at once: the GLP-1 receptor (the same target as Ozempic/Wegovy, which suppresses appetite) and the glucagon receptor (which boosts energy expenditure and burns fat). The dual action aims to produce greater weight loss than GLP-1-only drugs by also ramping up calorie burning.

Trial Status

DA-1726 is in an ongoing Phase 1 first-in-human trial (NCT06252220). Part 3 (higher-dose cohort, 48mg and 64mg target doses) completed dose titration on July 9, 2026, with ~40 subjects randomized 4:1 active to placebo. Prior Phase 1 MAD results (Jan 2026) showed 9.1% mean weight loss at the 48mg dose over 8 weeks. Topline Part 3 data is expected in Q4 2026.

The Two-Sided Case

▲ Bull Case5

Early Phase 1 data showed 9.1% mean weight loss at 48mg over 8 weeks — competitive with tirzepatide and superior to semaglutide in preclinical head-to-heads (source: MetaVia Jan 5, 2026 press release via ir.metaviatx.com)

The dual GLP-1/glucagon mechanism is differentiated from pure GLP-1 agonists, potentially preserving lean muscle mass while burning fat, which could be a significant commercial advantage (source: MetaVia ADA 2024 poster)

Analyst consensus is overwhelmingly bullish: 7 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $19.33 — over 1,100% implied upside from the ~$1.70 stock price

The ~$8M market cap means even modest positive data in Q4 2026 could drive a multi-bagger move given the thin float and low institutional ownership

Patent protection secured through 2041 provides a long exclusivity runway if the drug ultimately succeeds (source: edgen.tech Feb 13, 2026)

▼ Bear Case6

Only in Phase 1 — years and hundreds of millions of dollars away from potential approval, with no guarantee of Phase 2/3 success

Brutal competitive landscape: Novo Nordisk's semaglutide (Wegovy), Eli Lilly's tirzepatide (Zepbound), and Boehringer/Zealand's survodutide (16.6% Phase 3 weight loss) are all ahead and better-funded (source: Boehringer Ingelheim Phase 3 survodutide results)

Severe dilution risk: company expanded its ATM offering from $2.3M to $4.0M and already sold $2.1M — the remaining capacity represents ~27% of the ~$8M market cap

Institutional support is minimal and fading: UBS nearly fully exited (-99.9%), total institutional holdings are tiny (Vanguard ~$8K, Citadel ~$103K, Geode ~$40K)

Stock has collapsed ~91% from its 52-week high of $19.03 to ~$1.70, suggesting either a value trap or severe market skepticism about commercial viability

Phase 1 Part 3 data is not a binary approval catalyst — even strong results only advance to Phase 2, with many failure points ahead

Upcoming Catalysts

Q4 2026: Topline Phase 1 Part 3 data readout for higher-dose cohorts (48mg and 64mg) — the primary near-term catalyst
Potential Phase 2 trial initiation in 2027 if Part 3 data is positive
Ongoing MASH data updates for vanoglipel (DA-1241), a separate pipeline asset

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MetaVia Inc. 8-K MTVA ·Originating report

Sources · 12

Hover a chip for the title

1 ir.metaviatx.com2 prnewswire.com3 ir.metaviatx.com4 minichart.com.sg5 fiercebiotech.com6 ir.metaviatx.com7 edgen.tech8 prnewswire.com9 boehringer-ingelheim.com10 clinicaltrials.gov11 sec.gov12 sec.gov